QIAGEN achieves Personalized Healthcare milestone with U.S. approval of companion diagnostic for colorectal cancer
QIAGEN N.V. announced it has received U.S. Food and Drug Administration (FDA) approval to market the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer. The U.S. FDA approval of the KRAS test kit marks a milestone in QIAGEN’s global expansion of its Personalized Healthcare franchise.
“We are very pleased to receive FDA approval to launch our therascreen KRAS test in the United States and to play a role in transforming the care of colorectal cancer patients. This approval marks an important step for QIAGEN, but also an important step in Personalized Healthcare, as we are now launching a major molecular companion diagnostic product in the U.S.,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “With a growing portfolio of innovative tests and efficient automation platforms, we are proud to be helping to make healthcare more effective, providing ways for payers to more efficiently use healthcare resources and, most important, making a positive impact on the care of patients.”
Other news from the department research and development
These products might interest you

Vericheck ddPCR™ Empty-Full Capsid Kit by Bio-Rad Laboratories
Empty-to-Full Capsid Ratio Analysis For AAV-based Gene Therapy
Results within a day! Accurately measure protein & DNA simultaneously using ddPCR Technology

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World PCR
This groundbreaking and highly versatile molecular technique of PCR allows us to amplify tiny amounts of genetic material on a large scale and analyze them in detail. Whether in medical diagnostics, forensic DNA analysis or research into genetic diseases - PCR is an indispensable tool that gives us deep insights into the world of DNA. Immerse yourself in the fascinating world of the polymerase chain reaction (PCR)!

Topic World PCR
This groundbreaking and highly versatile molecular technique of PCR allows us to amplify tiny amounts of genetic material on a large scale and analyze them in detail. Whether in medical diagnostics, forensic DNA analysis or research into genetic diseases - PCR is an indispensable tool that gives us deep insights into the world of DNA. Immerse yourself in the fascinating world of the polymerase chain reaction (PCR)!
Last viewed contents

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Mobile gold fingers
